首页> Leukemia> Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

导出 OA

翻译打印收藏纠错

第一作者： T P,Hughes

第一单位： Division of Haematology, SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia.

作者： T P,Hughes ^[1] ; B,Leber ^[2] ; F,Cervantes ^[3] ; N,Spector ^[4] ; R,Pasquini ^[5] ; N C D,Clementino ^[6] ; A P,Schwarer ^[7] ; P E,Dorlhiac-Llacer ^[8] ; F-X,Mahon ^[9] ; D,Rea ^[10] ; A,Guerci-Bresler ^[11] ; S,Kamel-Reid ^[12] ; I,Bendit ^[13] ; S,Acharya ^[14] ; T,Glynos ^[15] ; D,Dalal ^[15] ; S,Branford ^[16] ; J H,Lipton ^[17]

作者单位： Division of Haematology, SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia. ^[1] Clinical Pathology, McMaster University, Hamilton, Ontario, Canada. ^[2] Department of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain. ^[3] Departamento de Clínica Médica/FM, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. ^[4] Division of Hematology and Medical Oncology, Federal University of Paraná, Curitiba, Brazil. ^[5] Hospital Das Clinicas da UFMG, Belo Horizonte, Brazil. ^[6] Department of Hematology, Alfred Hospital, Melbourne, Victoria, Australia. ^[7] Department of Hematology, Hospital das Clinicas FMUSP, São Paulo, Brazil. ^[8] Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Inserm U1035, Université Victor Ségalen, Bordeaux, France. ^[9] Unité de Thérapie Cellulaire et Clinique Transfusionnelle, Service des Maladies du Sang et EA3518, Hôpital Saint-Louis, Paris, France. ^[10] Department of Hematology, Brabois Hospital, Vandoeuvre-lès-Nancy, Vandoeuvre, France. ^[11] Clinical Laboratory Genetics, Genome Diagnostics, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada. ^[12] Hematology Unit, Faculty of Medicine, University of São Paulo, São Paulo, Brazil. ^[13] Novartis Healthcare Pvt Ltd, Hyderabad, India. ^[14] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. ^[15] Leukaemia Unit, Centre for Cancer Biology, SA Pathology, University of South Australia and University of Adelaide, Adelaide, South Australia, Australia. ^[16] Blood and Marrow Transplant Service, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. ^[17]